Atlas Trials

Tipranavir/Ritonavir vs. Genotypically Defined Protease Inhibitor/Ritonavir in HIV Patients (RESIST-2)

Clinical trial NCT00144170 · COMPLETED

Trial details

NCT number
NCT00144170
Sponsor
Boehringer Ingelheim
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
HIV Infections
Start date
2003-02-01
Primary completion
2008-10-01
Enrollment
882

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.